leuprolide

(redirected from Eligard)
Also found in: Medical.
Related to Eligard: Lupron

leu·pro·lide

 (lo͞o′prō-līd′)
n.
A drug that is a synthetic polypeptide analog of naturally occurring gonadotropin-releasing hormone, C29H84N16O12, used in its acetate form to treat advanced prostate cancer.

Mentioned in ?
References in periodicals archive ?
Ellison was the Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, where he was responsible for several key oncology products including Eloxatin (oxaliplatin) for colorectal cancer and Eligard (leuprolide acetate for injectable suspension) for prostate cancer.
This agreement provides Atrix with a royalty on net sales of the Eligard products following registration.
Atrix is developing two additional Eligard products that release leuprolide acetate over a period of three and four months using Atrix's Atrigel(R) Depot drug delivery system.
Fort Collins, CO) announced that the United States Patent and Trademark Office issued United States Patent 6,565,874, which effectively extends patent protection for the prostate cancer products franchise, Eligard (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer, to 2018.
TOLMAR Pharmaceuticals has the exclusive distribution rights for ELIGARD in the U.
The FDA has not made any conclusions about whether diabetes or these cardiovascular diseases are caused by treatment with these drugs, which are available in generic formulations and as brand-name products (Lupron, Eligard, Synarel, Trelstar, Vantas, Viadur, and Zoladex).
QLT has two marketed products: Visudyne for the treatment of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular histoplasmosis and Eligard for the palliative treatment of advanced prostate cancer.
8) nmol/L for Eligard, Lupron, Suprefact, Trelstar and Zoladex groups, correspondingly (Table 2).
Atrix has obtained FDA approval for the one-month Eligard 7.
The market is currently driven by the use of hormonal therapies: AstraZeneca's Zoladex (goserelin) and Casodex (bicalutamide), TAP Pharmaceutical Products' (Abbott/Takeda) Lupron (leuprolide subcutaneous injection or intramuscular depot), Sanofi-Aventis/Astellas Pharma's Eligard (leuprolide subcutaneous depot) and Bayer Schering Pharma's Viadur (leuprolide subcutaneous implant).
HC Royalty acquired a royalty interest in Eligard European sales from Medigene AG for $18 million.
Table 18: Prostate Cancer, Global, Eligard, Effect on PSA Level, 2010 64